Association of NUDT15 gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis
Open Access
- 5 October 2023
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 109 (4) , 1053-1068
Abstract
6-mercaptopurine (6-MP) serves as the backbone in the maintenance regimens of acute lymphoblastic leukemia (ALL). We aimed to evaluate the influence of NUDT15 gene polymorphism on the risk of myelosupression, hepatotoxicity and interruption of 6-MP, as well as treatment efficacy and dose of 6-MP in ALL patients. A total of 24 studies with 3,374 patients were included in this meta-analysis. We found 9-fold higher risk of 6-MP induced leukopenia (odds ratio [OR] =9.00, 95% confidence interval [CI]: 3.73-21.74) and 2.5-fold higher risk of 6-MP-induced neutropenia (OR=2.52, 95% CI: 1.72-3.69) for NUDT15 c.415C>T variant carriers in the dominant model. Moreover, we found that the dose intensity of 6-MP in ALL patients with one NUDT15 c.415C>T variant alleles (CT) was 19% less than that in wild-type patients (CC) (mean differences: 19.43%, 95% CI: -25.36 to -13.51). The tolerable dose intensity of 6-MP in NUDT15 c.415C>T homozygote variant (TT) and heterozygote variant (CT) carriers was 49% and 15% less than that in wild-type patients, respectively. The NUDT15 c.415C>T variant group (CT+TT) had seven times (OR=6.98, 95% CI: 2.83-17.22) higher risk of developing 6-MP intolerance than the CC group. However, NUDT15 c.415C>T polymorphism did not appear significantly associated with hepatotoxicity, treatment interruption or relapse incidence. We concluded that NUDT15 c.415C>T was a good predictor for 6-MP-induced myelosuppression in ALL patients. The dose intensity of 6-MP in ALL patients with NUDT15 c.415C>T variants was significantly lower than that in wild-type patients. This research provided a basis for further investigation into relations between NUDT15 gene and adverse reaction, treatment efficacy and dose intensity of 6-MP.Keywords
This publication has 71 references indexed in Scilit:
- Thiopurines: Factors influencing toxicity and responseBiochemical Pharmacology, 2010
- Adverse reactions to azathioprine cannot be predicted by thiopurine S‐methyltransferase genotype in Japanese patients with inflammatory bowel diseaseJournal of Gastroenterology and Hepatology, 2009
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementPLOS Medicine, 2009
- Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 studyLeukemia, 2008
- Acute lymphoblastic leukaemiaThe Lancet, 2008
- Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity*1Clinical Pharmacology & Therapeutics, 2004
- Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or AzathioprineJournal of Clinical Oncology, 2001
- Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene LocusJNCI: Journal of the National Cancer Institute, 1999
- The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populationsPharmacogenetics, 1999
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990